rs121918387 — APOB ApoB-67 frameshift

ApoB-67 — When Too Little Cholesterol Becomes a Problem

Apolipoprotein B (ApoB) is the structural backbone of every VLDL and LDL particle¹¹ VLDL and LDL particle
Very low-density lipoprotein (VLDL) is assembled in the liver and exports triglycerides to peripheral tissues; LDL is the remnant particle that delivers cholesterol to cells. Both require ApoB-100 as their obligate structural protein. Without functional ApoB, the liver cannot export triglycerides, and without efficient VLDL secretion, fat accumulates within hepatocytes. The rs121918387 variant introduces a single thymine deletion at coding position c.9200 that shifts the reading frame at codon 3,067 — producing a truncated protein, ApoB-67, containing approximately 3,040 amino acids instead of the normal 4,536. The result is a carrier phenotype unlike most genetic risk variants: dramatically low cholesterol that protects the heart, but at the cost of impaired hepatic lipid export and fat-soluble vitamin transport.

The Mechanism

Welty et al. 1991²² Welty et al. 1991
Welty FK et al. A truncated species of apolipoprotein B (B67) in a kindred with familial hypobetalipoproteinemia. J Clin Invest identified this variant in a large kindred and showed that seven of twelve children of the proband had hypobetalipoproteinemia. The truncated ApoB-67 protein is detectable in plasma within VLDL and LDL fractions, but at very low concentrations — consistent with impaired secretion and accelerated clearance. Unlike the full-length ApoB-100 particle which is cleared primarily through LDL receptors in the liver, truncated ApoB particles are cleared rapidly via megalin receptors³³ cleared rapidly via megalin receptors
Megalin (LRP2) is a multi-ligand endocytic receptor expressed on kidney proximal tubular cells and other epithelia; it binds and internalizes truncated ApoB particles more efficiently than LDL receptors handle full-length ApoB-100 in renal proximal tubular cells, which further depletes circulating levels.

The liver consequence is the flip side: because VLDL secretion is impaired, the triglycerides that would normally be packaged and exported accumulate as intracellular lipid droplets. Four interconnected mechanisms drive liver injury in APOB-FHBL: intracellular triglyceride accumulation from failed VLDL export, endoplasmic reticulum stress from defective ApoB protein folding, oxidative damage from reactive oxygen species generated by excess lipid, and impaired autophagy of lipid-laden organelles.

The Evidence

The cardiovascular protection from APOB truncation mutations is substantial and well-replicated. Welty 2020⁴⁴ Welty 2020
Welty FK. Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease. Curr Opin Lipidol synthesized data from 12 case-control studies involving approximately 58,000 individuals and found that apoB truncation mutations were associated with a 72% reduction in coronary heart disease (OR 0.28, 95% CI 0.12–0.64; P=0.002). This mirrors the pharmacological effect of PCSK9 inhibitors, which lower LDL by similar magnitudes — supporting APOB truncation as a natural Mendelian randomization model for LDL reduction.

The hepatic risk, however, is real and common. A retrospective cohort study⁵⁵ retrospective cohort study
Sürücü Kara et al. 2025. Clinical and biochemical spectrum of APOB-related hypobetalipoproteinemia: Insights from a retrospective cohort. J Clin Lipidol of 15 APOB-FHBL patients found hepatosteatosis on liver ultrasound in 73.3%, and elevated transaminases in 20–27%. Median LDL cholesterol was 25.7 mg/dL — dramatically below the normal range. Vitamin D insufficiency affected 66.7% of patients, and vitamin E deficiency 26.7%, consistent with reduced fat-soluble vitamin transport by apoB-containing lipoproteins.

Heterozygous carriers are usually mildly affected, but approximately 5–10% develop more severe nonalcoholic steatohepatitis⁶⁶ nonalcoholic steatohepatitis
NASH: inflammation and fibrosis superimposed on fatty liver, driven by oxidative stress, lipotoxicity, and immune activation. In biallelic (homozygous) carriers, the clinical picture is substantially more severe: severe intestinal lipid malabsorption, profound fat-soluble vitamin deficiency, and risk of cirrhosis and hepatocellular carcinoma have all been documented.

Practical Actions

Heterozygous carriers of the ApoB-67 deletion should be proactively monitored for hepatic steatosis and fat-soluble vitamin status, since the very low LDL that defines this genotype can be falsely reassuring. Because ApoB-containing lipoproteins are the main carriers of vitamins A, D, E, and K through the bloodstream, impaired VLDL secretion reduces circulating levels of all four — regardless of dietary intake. Annual monitoring of serum 25-hydroxyvitamin D, vitamin E (alpha-tocopherol), and vitamin A (retinol) is warranted. Liver enzymes (ALT, AST, GGT) should be checked at least annually; if elevated or if steatosis is found on imaging, hepatology referral is appropriate. Fat restriction can reduce hepatic triglyceride accumulation, but should be balanced against the need for adequate fat-soluble vitamin absorption.

Interactions

APOB-FHBL interacts meaningfully with other APOB variants. Compound heterozygosity or homozygosity for APOB truncation alleles — as can occur when two carriers reproduce — produces a biallelic phenotype resembling abetalipoproteinemia, with severe fat malabsorption and progressive neurological deterioration from vitamin E deficiency. Related APOB truncation variants include rs5742904 (ApoB-31), rs267607000 (ApoB-46), and rs1801702 (ApoB-87). Carriers of multiple truncation alleles in trans have been reported with severe liver disease, retinal degeneration, and peripheral neuropathy.

The hepatic steatosis mechanism in APOB-FHBL is distinct from APOE-mediated dyslipidemia (rs429358, rs7412). APOE ε4 causes elevated LDL and remnant lipoproteins; APOB truncation causes failed VLDL export and intrahepatic fat trapping. The two mechanisms converge on liver disease risk but through opposite lipid-level phenotypes and require very different clinical responses.